Global Chronic Disease Management Market - 2023-2030

Overview

Global Chronic Disease Management Market reached US$ 4.8 billion in 2022 and is expected to reach US$ 14.6 billion by 2030, growing with a CAGR of 11.4% during the forecast period 2023-2030.

The burden of chronic illness is rapidly rising all across the world. Unfortunately, the majority of these illnesses are chronic and require lifelong pharmaceutical use to be treated. The global market for chronic disease management driving by factors such as increasing prevalence of chronic disease, rising awareness regarding disease management, collaboration among major players for development of advanced solutions to manage the chronic diseases.

The supply of medical services, technologies, and solutions geared on helping people manage chronic health disorders like diabetes, cardiovascular illnesses, respiratory diseases, and more is included in the chronic disease management market. Due to reasons such the rising incidence of chronic diseases, the aging population, technological developments, and a greater emphasis on preventative healthcare, this industry has been expanding.

Spending on healthcare has increased as economies in the Asia-Pacific area have expanded. This offers chances for investing in healthcare technologies and solutions, such as those pertaining to the management of chronic diseases. The growing aging of the population in several countries such as China and India in the region has increased the prevalence of chronic diseases. The demand for efficient management solutions is further highlighted by this demographic trend.

Dynamics

Technological Advancements

For instance, in October 2022, the precision engagement platform for chronic illnesses was developed by Sweetch, a pioneer in digital therapeutics, and an update to the platform was released in an effort to improve patient compliance. Chronic condition patient non-compliance with recommended behavior and treatment regimens results in significant human misery and annual overspending of hundreds of billions of dollars. Even the most effective therapy needs regular, tailored interventions that go beyond the hospital and clinic to engage patients in the context of their everyday life in order to improve clinical outcomes.

Currently, scalable delivery of such therapies is not possible through human-dependent chronic disease management programs. At every stage of the patient's journey toward better health, Sweetch uses a combination of artificial intelligence (AI) and emotional intelligence (EI) behavioral science technology to transform millions of data points into hyper-personalized recommendations. These recommendations are delivered to patients at the appropriate time, in the appropriate voice, and with the appropriate context.

Active Major Players in Chronic Disease Management Solutions

As of January 2023, the first chronic disease management solution from Valencell is intended to assist patients with hypertension in better and more consistent blood pressure monitoring and maintaining treatment adherence. Without the use of uncomfortable or cumbersome cuffs, the device is intended to test blood pressure in under a minute using a small probe on the middle finger. The device's photoplethysmography (PPG) sensors measure blood flow patterns using reflected light.

In order to generate a blood pressure reading, proprietary AI algorithms will be processed along with physical attributes from PPG datasets made up of more than 7,000 patients. The device's built-in screen then shows the diastolic and systolic values, which are subsequently transferred via Bluetooth to the app.

Collaboration Among Major Players to Develop Advanced Solution

For instance, in November 2022, MedStar Health, a Maryland-based health system, and the precision medicine technology firm Zephyr AI, Inc., collaborated in order to enhance outcomes for chronic diseases, starting with type 2 diabetes (T2D). The cooperation will use MedStar Health's de-identified T2D datasets and patient management experience to advance the development of Zephyr AI's Insights predictive analytics product. The tool is intended to decrease negative outcomes such end-stage chronic renal disease, dialysis, foot ulcers, and amputations and enhance the timeliness of T2D therapies.

Together, Zephyr AI and MedStar Health can create technology that expands the promise of precision medicine to chronic illnesses and supports our current programs to help diabetics achieve better outcomes and spend less money. The cooperation is a part of a bigger initiative to improve patient outcomes by utilizing AI to solve unmet needs in precision medicine, from prevention to therapy. The alliance intends to increase prediction accuracy for diabetes care using precision medicine by upgrading the Insights tool.

Digital Therapeutics Play an Important Role in Chronic-Disease Management

Globally, the burden of chronic diseases has been rising and is predicted to do so in the future. Seventy-five percent of fatalities globally in 2010 and 79% in 2020 were caused by or contributed to by chronic diseases (including cardiovascular disease, cancer, diabetes, and respiratory disease). Experts estimate that by 2030, chronic diseases would be responsible for up to 84% of all global deaths. Digital medicines have the potential to significantly enhance patients' lives by providing better ways to manage chronic health issues, lower the burden of disease, give better clinical outcomes, and assist healthcare practitioners in making more educated treatment decisions.

Managing chronic conditions requires more than just taking medication; it also requires routine evaluation and a change in lifestyle. In order to enhance patient compliance with recommended medications, diets, and lifestyles, clinicians need improved end-to-end solutions that actively and thoroughly monitor patient health.

By overcoming these obstacles, digital technology can significantly contribute to a better understanding of disease management. The fact that over two thirds of the world's population now has internet access demonstrates the potential for digital therapies to have a significant impact.

High Costs for Designing and Impletation of Chronic Disease Management Platform

Effective chronic disease management solutions, such as software programs, medical equipment, and platforms for integrating data, require a significant investment in research and development. These expenses may hinder innovation and restrict the entry of new competitors. To incorporate chronic illness management solutions into their current workflows, healthcare providers frequently need to invest in infrastructure, training, and support systems.

Implementation and integration expenses can be high, especially for larger healthcare organizations. Solutions for managing chronic diseases call for ongoing upkeep, upgrades, and technical assistance. Budgets may be put under stress by these continuous expenses, especially in hospital settings with little resources.

Patient Engagement Challenges

Problems with patient engagement are a major barrier to efficient management of chronic diseases. Successful outcomes depend on including patients in their own care, but there are a number of issues that can make this difficult. Many patients might not fully comprehend their chronic illnesses, the significance of managing them, or the tools and resources accessible to them. Their desire to participate in their own care may be diminished by this ignorance.

Complex treatment plans incorporating drugs, dietary adjustments, exercise routines, and other factors are necessary for several chronic conditions. Patients may find it difficult to manage these complex strategies, which might result in non-compliance.However, not all patients have access to cellphones, computers, or steady internet connections, despite the fact that digital tools and apps can improve patient participation. Certain communities may not be able to use technology-driven solutions because of the digital divide.

Segment Analysis

The global chronic disease management market is segmented based on type, service type, delivery mode, indication, end-user and region.

Versatility, Durability and Ability to Set and Harden Even Underwater

Diabetes segment has significant market share in chronic disease management market in 2022. The most frequent cause of renal failure that necessitates dialysis or a kidney transplant is diabetes. Over the past 30 years, kidney failure has become significantly more common in the United States, where diabetes is now responsible for half of all new cases. Diabetes-related chronic kidney disease (CKD) is widespread, morbid, and expensive.

According to the International Diabetes Federation, 537 million people worldwide had diabetes in 2021, and that number is projected to rise to 784 million by the year 2045. Over 25% of patients with diabetes have CKD, and it's been calculated that 40% of diabetics may eventually get the disease. The prevalence of CKD linked to diabetes has expanded proportionally as the prevalence of diabetes has increased.

Geographical Penetration

Chronic Disease Prevalence, Rising Awareness, and Advanced Healthcare Infrastructure

North America has been a dominant force in the global chronic disease management market. One or more chronic diseases, such as diabetes, cancer, heart disease, and stroke, affect six out of ten Americans. These and other chronic diseases are the main contributors to health care costs as well as the major causes of death and disability in the United States.

Approximately one in ten Americans, or more than 37 million people, have diabetes, according to the Centers for Disease Control and Prevention (CDC). 90% to 95% of them have type 2 diabetes, a chronic disease that can cause immunological, neurological, and cardiovascular problems that have a significant influence on quality of life. According to the American Diabetes Association, diabetes is also thought to account for approximately one in every seven dollars spent on healthcare in the United States.

Through the use of digital health-based interventions, the 30-day readmission rate for patients who experienced an AMI was reduced by 50%, according to a US study by Johns Hopkins and Corrie Health involving more than a thousand patients. The study included continuous vitals monitoring with connected devices, educational materials on procedures, risk factors, and lifestyle changes, medication management with reminders and adherence tracking, connection with the care team, mood tracking, and the ability to view drug side effects.

Competitive Landscape

The major global players in the market include Allscripts Healthcare Solutions Inc., TriZetto Corporation, Siemens Healthcare Private Limited, IBM, Pegasystems Inc., Koninklijke Philips NV, EXL Healthcare, Infosys Limited, ScienceSoft USA Corporation and ZeOmega.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global chronic disease management market. Global primary care responses to the coronavirus disease 2019 (COVID-19) pandemic have prioritized acute and urgent care for COVID-19 patients and involved a large number of practitioners in COVID-19 vaccination counseling and administration.

Chronic disease management (CDM), including treatment for illnesses including hypertension, diabetes, and cancer, has frequently been completely or partially disrupted as a result of this prioritization. The effects have been more severe for persons who have chronic illnesses. Heart disease, diabetes, cancer, chronic renal disease, chronic obstructive pulmonary disease, and obesity all raise the risk of developing a serious illness from COVID-19.

Both disease prevention (such as promoting a healthy diet and regular exercise, screening for cancer and other conditions, and receiving oral health care) and disease management (such as educating patients about medications to control hypertension, diabetes, asthma, and other chronic conditions) place a strong emphasis on safety and mitigation.

Russia-Ukraine War Impact Analysis

Healthcare infrastructure, including hospitals, clinics, and medical supply lines, can be severely disrupted by conflict and war. The accessibility and availability of healthcare services, including those for managing chronic diseases, could be hampered by this disturbance. Access to necessary pharmaceuticals and medical supplies may be hampered in conflict-affected areas.

Chronic disease patients depend on a consistent supply of pharmaceuticals, and any disruption to this supply chain could have detrimental effects on their health. Mass population displacement, particularly of people with chronic illnesses, can result from conflict. Displaced people may have difficulty getting the right medical care, medicines, and support services, which can have a negative impact on their health.

By Type

• Solution
• Services

By Service Type

• Consulting Service
• Implementation Service
• Educational Service
• Others

By Delivery Mode

• On-Premise Solution
• Cloud-Based Solution
• Web-Based

By Indication

• Cardiovascular Diseases (CVD)
• Diabetes
• Chronic Obstructive Pulmonary Disorders (COPD)
• Arthritis
• Asthma
• Cancer
• Others

By End-user

• Healthcare Providers
• Healthcare Payers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In March 2023, Royal Philips, a leader in health technology launched Philips Virtual Care Management, a comprehensive portfolio of adaptable solutions and services. Through lowering emergency room visits and lowering the cost of care through improving chronic disease management, Philips Virtual Care Management can lessen the burden on hospital employees.
• In October 2022, Aptar Pharma introduced a new disease management platform to assist patients as they navigate the treatment process. With the addition of this new platform, Aptar Pharma is able to provide patients across a variety of therapeutic areas with a comprehensive, end-to-end solution that supports them from the preventive and diagnosis phases through illness treatment. The Aptar Digital Health Disease Management Platform embodies the company's dedication to providing creative, compliant, and best-in-class solutions to improve the management of chronic diseases for patients receiving at-home care.

Why Purchase the Report?

• To visualize the global chronic disease management market segmentation based on type, service type, delivery mode, indication, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic disease management market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic disease management market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies